サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1609694

日本のタンパク質治療薬市場レポート：製品、治療領域、機能、地域別、2024年～2032年

Japan Protein Therapeutics Market Report by Product (Monoclonal Antibodies, Human Insulin, Erythropoietin, Clotting Factors, Fusion Protein, and Others), Therapy Area, Function, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 115 Pages
納期
5～7営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
日本のタンパク質治療薬市場レポート：製品、治療領域、機能、地域別、2024年～2032年
出版日: 2024年12月05日
発行: IMARC
ページ情報: 英文 115 Pages
納期: 5～7営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

日本のタンパク質治療薬市場の市場規模は2023年に284億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに527億米ドルに達し、2024年から2032年の間に6.60%の成長率（CAGR）を示すと予測しています。がん、糖尿病、自己免疫疾患などの慢性疾患の罹患率が上昇し、標的を絞った効果的な治療を提供するタンパク質治療薬の需要が高まっていることが、市場を牽引しています。

本レポートで扱う主な質問

  • 日本のタンパク質治療薬市場はこれまでどのように推移し、今後どのように推移するのか？
  • COVID-19の日本のタンパク質治療薬市場への影響は？
  • 日本のタンパク質治療薬市場の製品別構成比は？
  • 日本のタンパク質治療薬市場の治療領域別の内訳は？
  • 日本のタンパク質治療薬市場の機能別の内訳は？
  • 日本のタンパク質治療薬市場のバリューチェーンにはどのような段階がありますか？
  • 日本のタンパク質治療薬の主な促進要因と課題は何か？
  • 日本のタンパク質治療薬市場の構造と主要プレーヤーは？
  • 日本のタンパク質治療薬市場における競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
  • 市場推定
  • 調査手法

第3章 エグゼクティブサマリー

第4章 日本のタンパク質治療薬市場：イントロダクション

  • 概要
  • 市場力学
  • 業界動向
  • 競合情報

第5章 日本のタンパク質治療薬市場情勢

  • 過去および現在の市場動向（2018～2023年）
  • 市場予測（2024～2032年）

第6章 日本のタンパク質治療薬市場：製品別の内訳

  • モノクローナル抗体（mAbs）
  • ヒトインスリン
  • エリスロポエチン
  • 凝固因子
  • 融合タンパク質
  • その他

第7章 日本のタンパク質治療薬市場：治療領域別の内訳

  • 代謝障害
  • 免疫疾患
  • 血液疾患
  • がん
  • ホルモン障害
  • 遺伝性疾患
  • その他

第8章 日本のタンパク質治療薬市場：機能別の内訳

  • 酵素および調節活性
  • 特別標的活動
  • ワクチン
  • タンパク質診断

第9章 日本のタンパク質治療薬市場：競合情勢

  • 概要
  • 市場構造
  • 市場プレーヤーのポジショニング
  • 主要成功戦略
  • 競合ダッシュボード
  • 企業評価象限

第10章 主要企業のプロファイル

第11章 日本のタンパク質治療薬市場：業界分析

  • 促進要因・抑制要因・機会
  • ポーターのファイブフォース分析
  • バリューチェーン分析

第12章 付録

目次
Product Code: SR112024A18904

Japan protein therapeutics market size reached US$ 28.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 52.7 Billion by 2032, exhibiting a growth rate (CAGR) of 6.60% during 2024-2032. The rising incidence of chronic diseases such as cancer, diabetes, and autoimmune disorders, which has led to an increased demand for protein therapeutics to provide targeted and effective treatment, is driving the market.

Protein therapeutics refers to a class of medical treatments that utilize proteins, typically biologically derived molecules, to prevent, manage, or cure various diseases and medical conditions. These therapeutic proteins can include antibodies, enzymes, hormones, or other functional proteins that play crucial roles in the body's biological processes. Protein therapeutics are designed to target specific disease mechanisms, such as binding to cancer cells or modulating immune responses, offering a high degree of precision and reduced side effects compared to traditional pharmaceuticals. They are often produced using biotechnology techniques, including recombinant DNA technology, and can be administered through injections, infusions, or other delivery methods. Examples of protein therapeutics include monoclonal antibodies used to treat autoimmune diseases like rheumatoid arthritis, insulin for diabetes management, and clotting factors for hemophilia. These therapies have revolutionized medicine, providing effective treatments for a wide range of diseases while continually advancing through ongoing research and development efforts.

Japan Protein Therapeutics Market Trends:

The protein therapeutics market in Japan is thriving due to several key drivers that have propelled its growth. Firstly, advancements in biotechnology have opened up new avenues for the development of protein-based drugs. This is exemplified by the increasing use of recombinant DNA technology, which allows for the production of therapeutic proteins with enhanced specificity and efficacy. Furthermore, the rising prevalence of chronic diseases, such as cancer, diabetes, and autoimmune disorders, has driven the demand for innovative treatment options. As a result, pharmaceutical companies are investing heavily in R&D to create novel protein therapeutics targeting these diseases. Additionally, the aging regional population is a significant driver of the protein therapeutics market. With a growing elderly population, there is an increased need for therapies that can address age-related conditions, further bolstering the demand for protein-based drugs. Moreover, the emerging trend toward personalized medicine that tailors treatments to individual patients is expected to drive the protein therapeutics market in Japan during the forecast period.

Japan Protein Therapeutics Market Segmentation:

Product Insights:

  • Monoclonal Antibodies (mAbs)
  • Human Insulin
  • Erythropoietin
  • Clotting Factors
  • Fusion Protein
  • Others

Therapy Area Insights:

  • Metabolic Disorders
  • Immunological Disorders
  • Hematological Disorders
  • Cancer
  • Hormonal Disorders
  • Genetic Disorders
  • Others

Function Insights:

  • Enzymatic and Regulatory Activity
  • Special Targeting Activity
  • Vaccines
  • Protein Diagnostics

Competitive Landscape:

The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.

Key Questions Answered in This Report:

  • How has the Japan protein therapeutics market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the Japan protein therapeutics market?
  • What is the breakup of the Japan protein therapeutics market on the basis of product?
  • What is the breakup of the Japan protein therapeutics market on the basis of therapy area?
  • What is the breakup of the Japan protein therapeutics market on the basis of function?
  • What are the various stages in the value chain of the Japan protein therapeutics market?
  • What are the key driving factors and challenges in the Japan protein therapeutics?
  • What is the structure of the Japan protein therapeutics market and who are the key players?
  • What is the degree of competition in the Japan protein therapeutics market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Japan Protein Therapeutics Market - Introduction

  • 4.1 Overview
  • 4.2 Market Dynamics
  • 4.3 Industry Trends
  • 4.4 Competitive Intelligence

5 Japan Protein Therapeutics Market Landscape

  • 5.1 Historical and Current Market Trends (2018-2023)
  • 5.2 Market Forecast (2024-2032)

6 Japan Protein Therapeutics Market - Breakup by Product

  • 6.1 Monoclonal Antibodies (mAbs)
    • 6.1.1 Overview
    • 6.1.2 Historical and Current Market Trends (2018-2023)
    • 6.1.3 Market Forecast (2024-2032)
  • 6.2 Human Insulin
    • 6.2.1 Overview
    • 6.2.2 Historical and Current Market Trends (2018-2023)
    • 6.2.3 Market Forecast (2024-2032)
  • 6.3 Erythropoietin
    • 6.3.1 Overview
    • 6.3.2 Historical and Current Market Trends (2018-2023)
    • 6.3.3 Market Forecast (2024-2032)
  • 6.4 Clotting Factors
    • 6.4.1 Overview
    • 6.4.2 Historical and Current Market Trends (2018-2023)
    • 6.4.3 Market Forecast (2024-2032)
  • 6.5 Fusion Protein
    • 6.5.1 Overview
    • 6.5.2 Historical and Current Market Trends (2018-2023)
    • 6.5.3 Market Forecast (2024-2032)
  • 6.6 Others
    • 6.6.1 Historical and Current Market Trends (2018-2023)
    • 6.6.2 Market Forecast (2024-2032)

7 Japan Protein Therapeutics Market - Breakup by Therapy Area

  • 7.1 Metabolic Disorders
    • 7.1.1 Overview
    • 7.1.2 Historical and Current Market Trends (2018-2023)
    • 7.1.3 Market Forecast (2024-2032)
  • 7.2 Immunological Disorders
    • 7.2.1 Overview
    • 7.2.2 Historical and Current Market Trends (2018-2023)
    • 7.2.3 Market Forecast (2024-2032)
  • 7.3 Hematological Disorders
    • 7.3.1 Overview
    • 7.3.2 Historical and Current Market Trends (2018-2023)
    • 7.3.3 Market Forecast (2024-2032)
  • 7.4 Cancer
    • 7.4.1 Overview
    • 7.4.2 Historical and Current Market Trends (2018-2023)
    • 7.4.3 Market Forecast (2024-2032)
  • 7.5 Hormonal Disorders
    • 7.5.1 Overview
    • 7.5.2 Historical and Current Market Trends (2018-2023)
    • 7.5.3 Market Forecast (2024-2032)
  • 7.6 Genetic Disorders
    • 7.6.1 Overview
    • 7.6.2 Historical and Current Market Trends (2018-2023)
    • 7.6.3 Market Forecast (2024-2032)
  • 7.7 Others
    • 7.7.1 Historical and Current Market Trends (2018-2023)
    • 7.7.2 Market Forecast (2024-2032)

8 Japan Protein Therapeutics Market - Breakup by Function

  • 8.1 Enzymatic and Regulatory Activity
    • 8.1.1 Overview
    • 8.1.2 Historical and Current Market Trends (2018-2023)
    • 8.1.3 Market Forecast (2024-2032)
  • 8.2 Special Targeting Activity
    • 8.2.1 Overview
    • 8.2.2 Historical and Current Market Trends (2018-2023)
    • 8.2.3 Market Forecast (2024-2032)
  • 8.3 Vaccines
    • 8.3.1 Overview
    • 8.3.2 Historical and Current Market Trends (2018-2023)
    • 8.3.3 Market Forecast (2024-2032)
  • 8.4 Protein Diagnostics
    • 8.4.1 Overview
    • 8.4.2 Historical and Current Market Trends (2018-2023)
    • 8.4.3 Market Forecast (2024-2032)

9 Japan Protein Therapeutics Market - Competitive Landscape

  • 9.1 Overview
  • 9.2 Market Structure
  • 9.3 Market Player Positioning
  • 9.4 Top Winning Strategies
  • 9.5 Competitive Dashboard
  • 9.6 Company Evaluation Quadrant

10 Profiles of Key Players

  • 10.1 Company A
    • 10.1.1 Business Overview
    • 10.1.2 Product Portfolio
    • 10.1.3 Business Strategies
    • 10.1.4 SWOT Analysis
    • 10.1.5 Major News and Events
  • 10.2 Company B
    • 10.2.1 Business Overview
    • 10.2.2 Product Portfolio
    • 10.2.3 Business Strategies
    • 10.2.4 SWOT Analysis
    • 10.2.5 Major News and Events
  • 10.3 Company C
    • 10.3.1 Business Overview
    • 10.3.2 Product Portfolio
    • 10.3.3 Business Strategies
    • 10.3.4 SWOT Analysis
    • 10.3.5 Major News and Events
  • 10.4 Company D
    • 10.4.1 Business Overview
    • 10.4.2 Product Portfolio
    • 10.4.3 Business Strategies
    • 10.4.4 SWOT Analysis
    • 10.4.5 Major News and Events
  • 10.5 Company E
    • 10.5.1 Business Overview
    • 10.5.2 Product Portfolio
    • 10.5.3 Business Strategies
    • 10.5.4 SWOT Analysis
    • 10.5.5 Major News and Events

11 Japan Protein Therapeutics Market - Industry Analysis

  • 11.1 Drivers, Restraints, and Opportunities
    • 11.1.1 Overview
    • 11.1.2 Drivers
    • 11.1.3 Restraints
    • 11.1.4 Opportunities
  • 11.2 Porters Five Forces Analysis
    • 11.2.1 Overview
    • 11.2.2 Bargaining Power of Buyers
    • 11.2.3 Bargaining Power of Suppliers
    • 11.2.4 Degree of Competition
    • 11.2.5 Threat of New Entrants
    • 11.2.6 Threat of Substitutes
  • 11.3 Value Chain Analysis

12 Appendix